Merck Announces Phase 3 HYPERION Study of WINREVAIR\u2122 (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults w

• click to rate

  Posted by Two Blokes Jun 23 - Filed in Stock - 4 views
  
  RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR\u2122 (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. HYPERION met its primary endpoint of time to clin.